Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 3 1

Status

Completed 6Terminated 2

Sponsor Class

INDUSTRY 4OTHER 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Endocrine 3NET 2Gastrointestinal 2Thoracic 1

Conditions

Neuroendocrine Tumors 7Neoplasms 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Stomach Neoplasms 4Esophageal Neoplasms 4Acromegaly 4Weight Loss 3Rectal Neoplasms 3Pancreatic Neoplasms 3Diarrhea 3Carcinoma 3Breast Neoplasms 3Vipoma 2Thymoma 2Somatostatinoma 2Pituitary Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Malnutrition 2Intestinal Obstruction 2Insulinoma 2Glucagonoma 2Colonic Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Neoplasms × Octreotide × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT00332969 2017-03-31

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Novartis

Phase 2 Completed
25 enrolled
Thoracic

Disease, Neoplasms, Thymoma

NCT00412061 2014-11-21

RADIANT-2

Novartis

Phase 3 Completed
429 enrolled 13 charts
Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT00250796 2010-01-07

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

University of New Mexico

Phase 2 Completed
12 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT00050635 2009-11-19

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Novartis

Phase 4 Completed
150 enrolled
Gastrointestinal

Diarrhea, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡